New antithrombotics for atrial fibrillation

Cardiovascular Therapeutics
Luke R E Bereznicki, Gregory M Peterson

Abstract

Atrial fibrillation (AF) is the most commonly occurring arrhythmia, and is a condition of both significant clinical and economic importance. An antithrombotic agent is considered mandatory as part of the management in most patients with AF. It has been conclusively demonstrated that long-term anticoagulation therapy can significantly reduce the risk of stroke in patients with nonvalvular AF. While vitamin K antagonists (VKAs) such as warfarin are highly effective, they possess numerous limitations that curtail their use, or make their use challenging for clinicians and patients. A new generation of anticoagulants are being investigated in phase III clinical trials in patients with AF. One or more of these agents have the potential to either replace or act as alternatives to VKA therapy in AF. This group includes the direct thrombin inhibitor, dabigatran, the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, and finally, the vitamin K analogue, tecarfarin. Additional agents are being developed in phase I or II clinical trials. The direct thrombin and factor Xa inhibitors are generally small, synthetic molecules with predictable pharmacokinetics, a predictable pharmacodynamic effect, few drug interactions and do no...Continue Reading

References

Sep 1, 1987·Archives of Internal Medicine·P A WolfW B Kannel
Jan 25, 1996·The American Journal of Cardiology·J MorleyP Kowey
May 1, 1996·British Journal of Clinical Pharmacology·G Y Lip, G D Lowe
Nov 20, 1998·Chest·A LaupacisD E Singer
Feb 19, 1999·Lancet·G Y Lip
Mar 12, 1999·Lancet·R G Dalton
May 20, 1999·Lancet·G Y Lip
May 26, 1999·JAMA : the Journal of the American Medical Association·M D Ezekowitz, J A Levine
Oct 3, 1999·Annals of Internal Medicine·M D Ezekowitz
Jan 13, 2000·Archives of Internal Medicine·T J BungardR T Tsuyuki
Feb 7, 2001·Chest·J AnsellD Matchar
Jun 13, 2001·JAMA : the Journal of the American Medical Association·B F GageM J Radford
Aug 29, 2001·Clinical Pharmacokinetics·H Takahashi, H Echizen
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Joshua S BennerJerry Avorn
Nov 9, 2002·BMJ : British Medical Journal·Anders Odén, Martin Fahlén
Apr 8, 2003·Thrombosis Research·Meyer-Michel Samama, Grigoris T Gerotziafas
Aug 28, 2003·JAMA : the Journal of the American Medical Association·Thomas J WangEmelia J Benjamin
Dec 24, 2003·Thrombosis and Haemostasis·Brian F GageHoward L McLeod
Feb 11, 2005·JAMA : the Journal of the American Medical Association·Gregory W AlbersUNKNOWN SPORTIF Executive Steering Committee for the SPORTIF V Investigators
Aug 5, 2005·The New England Journal of Medicine·Lars Osterberg, Terrence Blaschke
Sep 9, 2005·The New England Journal of Medicine·Marcello Di NisioHarry R Büller
Nov 4, 2005·The New England Journal of Medicine·Ronald J Campbell
Feb 14, 2007·Archives of Internal Medicine·Nicole L GlazerSusan R Heckbert
Apr 10, 2007·Journal of the American College of Cardiology·Shane B RowanRobert J Anderson
Feb 19, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Monica R McClainJames E Haddow

❮ Previous
Next ❯

Citations

Jun 10, 2011·Thrombosis and Haemostasis·Helen ManiEdelgard Lindhoff-Last
Sep 5, 2014·European Journal of Clinical Pharmacology·Hesham S Al-SallamiStephen B Duffull
Oct 26, 2012·Expert Opinion on Drug Safety·Imtiaz SalimAmar M Salam
Apr 30, 2014·Revista Española De Cardiología·M Dolores Vega-CocaTeresa Molina-López
Sep 3, 2011·Cardiovascular Therapeutics·Shaker A Mousa
May 1, 2013·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Nina WunderlichHorst Sievert
Apr 26, 2011·Journal of cardiology·Takeshi Yamashita
Nov 11, 2011·American Journal of Therapeutics·John C Somberg
Jun 16, 2012·Expert Review of Clinical Pharmacology·Stephen B Duffull
Jul 12, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Prakash C Deedwania, Grace W Huang
Jun 10, 2011·Current Opinion in Cardiology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

© 2021 Meta ULC. All rights reserved